FGF19 has been shown to stimulate glycogen synthesis and inhibit gluconeogenesis through insulin‐independent pathways.[38] Our clinical analysis showed that serum FGF19 levels were significantly decreased in the T2D‐NO group compared to the NGT‐NO group. The gene discussed is FGF19; the disease is type 2 diabetes mellitus.